Sarah Ashby - Psychemedics VP Counsel
| PMD Stock | USD 2.64 0.02 0.76% |
Insider
Sarah Ashby is VP Counsel of Psychemedics
| Address | 5220 Spring Valley Road, Dallas, TX, United States, 75254 |
| Phone | 978 206 8220 |
| Web | https://www.psychemedics.com |
Psychemedics Management Efficiency
The company has Return on Asset of (0.1176) % which means that on every $100 spent on assets, it lost $0.1176. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4763) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.3. The current year's Return On Capital Employed is expected to grow to -0.32. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Biehl | Sotera Health Co | 68 | |
| Nadia Altomare | Sera Prognostics | 53 | |
| Sally Turner | Sotera Health Co | N/A | |
| Alexander Dimitrief | Sotera Health Co | 65 | |
| Fredrik Netzel | Olink Holding AB | 53 | |
| Shaokun Chuai | Burning Rock BiotechLtd | 45 | |
| Zvi David | DarioHealth Corp | 63 | |
| Oskar Hjelm | Olink Holding AB | 39 | |
| Lehmann JD | Sotera Health Co | 56 | |
| Paul Kearney | Sera Prognostics | 56 | |
| Zhihong Zhang | Burning Rock BiotechLtd | 48 | |
| Kara Thornton | Neuronetics | N/A | |
| Yusheng Han | Burning Rock BiotechLtd | 45 | |
| Kristin Gibbs | Sotera Health Co | N/A | |
| MingChou Lee | Exagen Inc | N/A | |
| Sean MD | Sera Prognostics | N/A | |
| Andrew Macan | Neuronetics | 51 | |
| John Boniface | Sera Prognostics | 62 | |
| Dov Oppenheim | DarioHealth Corp | N/A | |
| Camilla Zuckero | Castle Biosciences | N/A | |
| Ryan Douglas | Exagen Inc | N/A | |
Management Performance
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.12 |
Psychemedics Leadership Team
Elected by the shareholders, the Psychemedics' board of directors comprises two types of representatives: Psychemedics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Psychemedics. The board's role is to monitor Psychemedics' management team and ensure that shareholders' interests are well served. Psychemedics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Psychemedics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Clinton Allen, Independent Director | ||
| Charles IV, Ex VP | ||
| Harry Connick, Independent Director | ||
| James Abely, Vice President General Counsel | ||
| Fred Weinert, Independent Director | ||
| Werner Baumgartner, Founder | ||
| Annette Baumgartner, Founder | ||
| Sarah Ashby, VP Counsel | ||
| Patrick Kinney, Secretary | ||
| Brian Hullinger, CEO President | ||
| Walter Tomenson, Independent Director | ||
| Charles Doucot, Executive Vice President | ||
| Michael Weisenhoff, Principal Manager | ||
| Raymond Kubacki, Chairman, CEO and Pres | ||
| James Dyke, Corporate VP of Sales and Marketing | ||
| Shannon Shoemaker, Chief Officer | ||
| Michael Schaffer, VP of Laboratory Operations | ||
| Neil Lerner, Vice President - Finance, Treasurer | ||
| Daniella Mehalik, Vice Finance |
Psychemedics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Psychemedics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.17) % | ||||
| Current Valuation | 15.54 M | ||||
| Shares Outstanding | 5.81 M | ||||
| Shares Owned By Insiders | 22.70 % | ||||
| Shares Owned By Institutions | 22.34 % | ||||
| Number Of Shares Shorted | 16.88 K | ||||
| Price To Earning | 92.08 X |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Psychemedics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Psychemedics Stock analysis
When running Psychemedics' price analysis, check to measure Psychemedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psychemedics is operating at the current time. Most of Psychemedics' value examination focuses on studying past and present price action to predict the probability of Psychemedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psychemedics' price. Additionally, you may evaluate how the addition of Psychemedics to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |
Is Psychemedics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.30) | Dividend Share 0.07 | Earnings Share (0.72) | Revenue Per Share 3.85 | Quarterly Revenue Growth (0.12) |
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.